Literature DB >> 19382489

Surgical or medical management of subperiosteal orbital abscess in children: a critical appraisal of the literature.

Saskia Coenraad1, Joeri Buwalda.   

Abstract

OBJECTIVE: Subperiosteal orbital abscesses (SPOA) are a complication of sinusitis. Traditional treatment of SPOA is surgical. Recently, a number of studies report successful medical treatment. To our knowledge, it is unclear which patients can benefit from medical management alone. Therefore, we questioned (1) what is the outcome of medical versus surgical treatment? (2) which patients can be cured with antibiotics alone? (3) what are the absolute criteria for surgical treatment?
METHODS: A structured search was conducted in PubMed, EMBASE and the Cochrane Library for relevant papers which were critically appraised.
RESULTS: Five studies addressing our clinical questions were included, one prospective case series and four retrospective studies. Evidence levels varied from 2b to 3. Overall, a high cure rate was achieved with combined modality treatment (95.3-100%). The cure rate of medical treatment alone varied between 26% and 93%. The outcome of medical treatment improved after prior selection of surgical cases. In general, responders to medical treatment had a medial abscess associated with ethmoid sinusitis. Criteria for initial surgical or medical management differed among authors. Most authors agreed upon initial surgical treatment for patients with non-medial abscesses, decreased visual acuity and signs of systemic involvement. Surgery was also indicated when lack of improvement or worsening of symptoms and signs after 48-72 hours of medical treatment were observed.
CONCLUSIONS: The outcome of surgical versus medical management of SPOA within and between studies could not be compared. Higher cure rates were observed when both modalities were combined. There is some evidence that medical treatment can cure medially located SPOA. Loss of visual acuity, non-medial abscess, clinical detoriation and failure to improve within 48 hours of antibiotic treatment can be considered as criteria for surgical treatment. In the absence of these criteria a trial of antibiotic treatment can be considered with close monitoring of the patient.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19382489

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  8 in total

Review 1.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

2.  Core curriculum illustration: subperiosteal abscess in an adult.

Authors:  Gary Merhar; Gustav Blomquist; David Nickels; Fred Mann
Journal:  Emerg Radiol       Date:  2013-07-25

3.  Approaches to subperiosteal orbital abscesses.

Authors:  Ibrahim Ketenci; Yaşar Unlü; Alperen Vural; Hakkı Doğan; Mehmet Ilhan Sahin; Erkun Tuncer
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-30       Impact factor: 2.503

4.  Management of orbital complications due to rhinosinusitis.

Authors:  V Siedek; A Kremer; C S Betz; U Tschiesner; A Berghaus; A Leunig
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-13       Impact factor: 2.503

5.  Is pyogenic ethmoidal osteitis the cause of complicated rhinosinusitis with subperiosteal orbital abscess?

Authors:  Ahmed Ragab; Rehab Monir Samaka
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-13       Impact factor: 2.503

6.  Imaging findings of the orbital and intracranial complications of acute bacterial rhinosinusitis.

Authors:  J W Dankbaar; A J M van Bemmel; F A Pameijer
Journal:  Insights Imaging       Date:  2015-08-08

7.  Acute MRSA sinusitis with intracranial extension and marginal vancomycin susceptibility.

Authors:  Parvathi S Kumar; Kenji M Cunnion
Journal:  Case Rep Pediatr       Date:  2013-09-11

Review 8.  Acute rhinosinusitis in children.

Authors:  Cheryl C Nocon; Fuad M Baroody
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.